<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02351024</url>
  </required_header>
  <id_info>
    <org_study_id>OXP005-001</org_study_id>
    <nct_id>NCT02351024</nct_id>
  </id_info>
  <brief_title>Phase I Study PK Study With OXP005 and Naprosyn</brief_title>
  <official_title>Study to Assess the Comparative Bioavailability and Pharmacokinetics of Naproxen From OXP005 Tablets (Test) And Naprosyn® Tablets (Reference) in Normal, Healthy, Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxford Pharmascience Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oxford Pharmascience Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Sponsor is developing a new form of naproxen (the study drug, OXP005), for the potential
      treatment of rheumatic and painful conditions. The study will compare the study drug to an
      already marketed formulation of prescription strength naproxen (Naprosyn® the reference
      product) by looking at how a single dose of the drug is taken up by the body. The safety and
      tolerability of the drug will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Comparative bioavailability of naproxen as measured by Tmax, Cmax, AUC, half-life</measure>
    <time_frame>Day 1 &amp; Day 8 single dose crossover</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>OXP005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OXP005</intervention_name>
    <arm_group_label>OXP005</arm_group_label>
    <other_name>Naproxen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naprosyn®</intervention_name>
    <arm_group_label>Naproxen</arm_group_label>
    <other_name>Naproxen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects and non-pregnant, non breast feeding healthy female subjects
             aged 18 to 55 years

          -  Body mass index 18.0 to 30.0 kg/m2

        Exclusion Criteria:

          -  History of or current significant diseases or conditions including any disease or
             condition affecting the haematopoietic, cardiovascular, renal, hepatic, endocrine,
             pulmonary, central nervous, immunological, dermatological, gastrointestinal or any
             other body system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quotient Clinical Ltd</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2015</study_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

